White House CDC nominee Schwartz advances to Senate vote

A divided hearing room

During the committee proceedings, witnesses debated Schwartz's qualifications and her ability to rebuild trust in an institution battered by controversy. Dr. Georges Benjamin, executive director of the American Public Health Association, endorsed Schwartz's nomination, saying she could rebuild CDC leadership and steer the agency toward bipartisan priorities such as foodborne disease outbreaks. "She could rebuild CDC leadership and focus on bipartisan concerns like foodborne disease outbreaks," Benjamin told the panel.

Not all voices in the hearing were supportive. Sean Kaufman, a biosafety expert, raised concerns about Schwartz's record and her preparedness for the demands of the role, telling lawmakers that the nominee needed to demonstrate deeper familiarity with the agency's scientific operations. His testimony added to a record that committee members said they would weigh ahead of the floor vote.

Cassidy's committee weighs the nomination

Cassidy's committee has framed the nomination as a test of whether the CDC can regain its footing after a turbulent period that included leadership disputes and public scrutiny of the agency's pandemic-era decisions. Cassidy, a physician and Republican from Louisiana, has signaled that he intends to use the confirmation process to press Schwartz on her plans for restoring staff morale, rebuilding laboratory capacity and modernizing the agency's data systems.

Uncertain path to confirmation

Schwartz's path to confirmation is not assured. Several senators have questioned her positions on vaccine policy and on the structural changes Kennedy has championed at the Department of Health and Human Services, which oversees the CDC. A handful of Democrats have indicated they could oppose her, while some Republicans have yet to announce their position, leaving the outcome uncertain as the nomination heads to the floor.

Beyond the confirmation fight, the broader controversy over the CDC's direction has spilled into public view. Critics have accused the administration of undermining the agency through budget pressures, personnel changes and the sidelining of career scientists. Supporters argue that Schwartz represents a return to traditional public health practice after years of politicization and that she is well placed to repair relationships with state and local health departments.

Broader battle over CDC's direction

The full Senate vote is expected in the coming weeks. If confirmed, Schwartz would inherit an agency that has lost several senior career officials in recent months and that faces a challenging respiratory virus season, continued concerns about avian influenza and routine but politically charged decisions about immunization schedules.

Public health groups have largely rallied behind Schwartz. The American Public Health Association's endorsement, combined with statements from former CDC directors and state health officials, reflects a desire among many in the field to see the agency placed under steady leadership. Opponents, including some biosafety advocates, have urged senators to scrutinize her record on laboratory safety and on the independence of the agency's scientific advisory committees.